BioGaia Deepens European Push With Expanded Ewopharma Distribution Deal

BioGaia AB ( ($SE:BIOG.B) ) just unveiled an update.

BioGaia AB has renewed and expanded its long-standing distribution agreement with Ewopharma, a pharmaceutical marketing and commercialization partner active in Central Eastern Europe and Switzerland. Under the new deal, Ewopharma will distribute a broad range of BioGaia’s probiotic portfolio in more than 15 European countries, leveraging its established network and local expertise.

The extension of this partnership is positioned as a key milestone in BioGaia’s international growth strategy, aimed at accelerating regional expansion and increasing the availability of its probiotic products to both consumers and healthcare professionals. By deepening collaboration with a trusted regional distributor, BioGaia reinforces its European footprint and signals a continued focus on scaling its presence through strategic alliances in core markets.

The most recent analyst rating on ($SE:BIOG.B) stock is a Hold with a SEK109.00 price target. To see the full list of analyst forecasts on BioGaia AB stock, see the SE:BIOG.B Stock Forecast page.

More about BioGaia AB

BioGaia AB is a Swedish probiotic company listed on the Mid Cap segment of Nasdaq Stockholm, specializing in the development, marketing, and sale of probiotic products targeting gut, immune, and oral health. With more than 35 years of microbiome research, the company distributes its products through local partners and its own channels in over 100 markets worldwide.

Average Trading Volume: 334,969

Technical Sentiment Signal: Strong Buy

Current Market Cap: SEK10.96B

See more insights into BIOG.B stock on TipRanks’ Stock Analysis page.